New pill shows promise for psoriasis in early trial

NCT ID NCT06176768

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested an oral drug called LY3972406 in 33 adults with moderate-to-severe plaque psoriasis. The study compared the drug to a placebo to see if it could reduce skin symptoms. Results will help determine if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3972406 (oral drug)
What this could lead to: If successful, this could lead to a new oral treatment option for moderate-to-severe plaque psoriasis.
What could go wrong: This is a small, early-phase trial with only 33 participants. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Accellacare - Winston-Salem

Winston-Salem, North Carolina, 27103, United States
Austin Institute for Clinical Research

Houston, Texas, 77056, United States
Center for Clinical Studies

Houston, Texas, 77004, United States
Clinical Science Institute

Santa Monica, California, 90404, United States
Conquest Research

Winter Park, Florida, 32789, United States
DermDox Centers for Dermatology

Camp Hill, Pennsylvania, 17011, United States
Dermatology Research Associates

Los Angeles, California, 90045, United States
Driven Research

Coral Gables, Florida, 33134, United States
Metropolitan Dermatology - Clark

Kenilworth, New Jersey, 07033, United States
Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, 08520, United States
Remington-Davis, Inc

Columbus, Ohio, 43215, United States
Schweiger Dermatology Group

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.